Zealand Pharma A/S ZEALAND PHARMA.../ DK0060257814 /
2024-06-25 6:33:45 PM | Chg. +53.77 | Volume | Bid2024-06-25 | Ask2024-06-25 | High | Low |
---|---|---|---|---|---|---|
857.41DKK | +6.69% | 16,182 Turnover: 13.99 mill. |
-Bid Size: - | -Ask Size: - | 894.50 | 815.00 |
GlobeNewswire
8:42 PM
Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900...
GlobeNewswire
5:02 PM
Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 90...
GlobeNewswire
06-20
Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose ...
GlobeNewswire
06-07
Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improveme...
GlobeNewswire
06-07
Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsenin...
GlobeNewswire
06-06
Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial ...
GlobeNewswire
05-31
Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia...
GlobeNewswire
05-29
Zealand Pharma to participate in upcoming healthcare investor conferences in June 2024
GlobeNewswire
05-23
Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low ...
GlobeNewswire
05-09
Zealand Pharma conference call on May 16 at 2pm CET (8am ET) to present first quarter 2024 financial...
GlobeNewswire
03-20
Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatm...
GlobeNewswire
02-26
Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated ...
GlobeNewswire
02-26
Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver dise...
GlobeNewswire
02-20
Zealand Pharma conference call on February 27 at 2pm CET (8am ET) to present full year 2023 financia...
GlobeNewswire
01-08
Zealand Pharma announces directed issue and private placement for gross proceeds of DKK 1.45 billion